Key result
In vitro aspirin resistance, revealed by PFA-100 closure time failure, was associated with significantly higher plasma vWF:RCo levels compared to good responders (159% vs 121%; P<0.01).
Why the study?
Does plasma von Willebrand factor level correlate with in vitro aspirin resistance detected by PFA-100 closure time in patients receiving aspirin?
Population
55 consecutive patients receiving aspirin (75-250 mg/d) and 32 untreated control subjects
Comparison
Aspirin 75-250 mg/d vs Untreated control subjects
Design
Cross-sectional
Authors
Loading...
Elevated vWF:RCo was associated with PFA-100 aspirin resistance; hypothesis-generating for vWF modulation before practice change.
Cross-Sectional (n=87)
Does plasma von Willebrand factor level correlate with in vitro aspirin resistance detected by PFA-100 closure time in patients receiving aspirin?
Absolute Event Rate: 159% vs 121%
p-value: p=< 0.01
In vitro aspirin resistance detected by PFA-100 closure time is correlated with increased plasma von Willebrand factor levels, suggesting vWF plays a pivotal role in PFA-100 cartridge performance.
Chakroun et al. (2003) conducted a cross-sectional in Aspirin therapy (n=87). In vitro aspirin resistance (bad responder status) vs. Aspirin good responders was evaluated on Plasma vWF:RCo levels (p=< 0.01). In vitro aspirin resistance, revealed by PFA-100 closure time failure, was associated with significantly higher plasma vWF:RCo levels compared to good responders (159% vs 121%; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: